Thus, thiostrepton, a direct inhibitor of FoxM1, which inhibits FoxM1 binding to genomic target sites (Hegde et al., 2011), may be a new approach to rheumatoid arthritis treatment. Here, FOXM1 is linked to rheumatoid arthritis.